Notícias e Atividades da Imbria Pharmaceuticals

Fusão, aquisição e financiamento envolvendo Imbria Pharmaceuticals.

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).

Veja o organograma con seus 11 executivos principais

Biografias mais buscadas da Imbria Pharmaceuticals

• Alvin Shih, Chief Executive Officer
• Charles Dunn, Director
• James Januzzi, Director

Recentes movimentos de executivos em Imbria Pharmaceuticals

• Alvin Shih antes Executive Chairman of the Board, agora é Chief Executive Officer  (Notícia publicada em 10 de abril de 2025).

Criar um alerta
para seguir os movimentos de executivos da Imbria Pharmaceuticals.

Imbria Pharmaceuticals possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Imbria Pharmaceuticals

• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - Press Releases - Media Center - Imbria
• Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 - Press Releases - Media Center - Imbria
• Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - Press Releases - Media Center - Imbria
• Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - Press Releases - Media Center - Imbria
• Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024 - Press Releases - Media Center - Imbria
• Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024 - Press Releases - Media Center - Imbria
• Press Releases - Media Center - Imbria
• Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24 - Press Releases - Media Center - Imbria
• View more press releases Close

Redes sociais sobre Imbria Pharmaceuticals

• Imbria Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Imbria Pharmaceuticals na LinkedIn, Twitter e YouTube